The subsequent development of targeted therapy with EGFR tyrosine kinase inhibitors (TKIs), such as a the first-generation (erlotinib, gefitinib), the second-generation (afatinib), and the third-generation (osimertinib) TKIs, has dramatically revolutionized the treatment landscape of NSCLC[23]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.